Another Tysabri Patient with PML – This Makes #9
June 22, 2009 at 5:03 pm EST | Tags: Drugs, Healthcare & Medicine, Tysabri
Presented by cshlpress…
Another MS patient on Biogen’s Tysabri has come down with progressive multifocal leukoencephalopathy (PML) bringing the total number of cases to 9 since the drug was OK’ed back onto the market in 2006.
This is the second case in June with the last infection reported on June 13th.
More than 56,000 patients have been treated with Tysabri and according to the drug’s label, the likelihood of contracting PML is 1:1000.
PML has received a lot of press recently due to the Tysabri infections, and to increased surveillance and press coverage. Last month, Roche/Genentech’s Raptiva, which is indicated for psoriasis, was pulled from the U.S. and EU market after three patients were diagnosed with PML, two of which died.
Additionally, MS drugs are not without serious side effects. In April, Novartis reported that one patient on Fingolimod (FTY720) came down with hemorrhaging focal encephalitis.
Stay tuned…
Anonymous Tip? Comments? Contact us: hr AT iguanabio DOT com
![[Loading...]](http://www.iguanabio.com/wp-content/themes/IguanaBio/images/ajax-loader.gif){kind=small}
